AR099707A1 - Composiciones y métodos para tratar trastornos renales - Google Patents
Composiciones y métodos para tratar trastornos renalesInfo
- Publication number
- AR099707A1 AR099707A1 ARP150100715A ARP150100715A AR099707A1 AR 099707 A1 AR099707 A1 AR 099707A1 AR P150100715 A ARP150100715 A AR P150100715A AR P150100715 A ARP150100715 A AR P150100715A AR 099707 A1 AR099707 A1 AR 099707A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- compositions
- inhibitor
- renal disorders
- treat renal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Métodos para el tratamiento de un trastorno renal, como enfermedad renal crónica o NASH, usando un inhibidor de galectina-3, como una pectina modificada (por ejemplo, GCS-100). Métodos para evaluar y/o controlar los efectos de un inhibidor de galectina-3, por ejemplo, para adaptar el régimen posológico del inhibidor durante la terapia. Reivindicación 7: El método de acuerdo con la reivindicación 6, en donde la estructura de la pectina modificada comprende homogalacturonano y/o ramnogalacturonano I.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461950806P | 2014-03-10 | 2014-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099707A1 true AR099707A1 (es) | 2016-08-10 |
Family
ID=54072328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150100715A AR099707A1 (es) | 2014-03-10 | 2015-03-10 | Composiciones y métodos para tratar trastornos renales |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170014446A1 (es) |
| EP (1) | EP3125908A4 (es) |
| JP (1) | JP2017512205A (es) |
| KR (1) | KR20160122855A (es) |
| CN (1) | CN106714812A (es) |
| AR (1) | AR099707A1 (es) |
| AU (1) | AU2015229658A1 (es) |
| CA (1) | CA2942320A1 (es) |
| IL (1) | IL247699A0 (es) |
| TW (1) | TW201618794A (es) |
| WO (1) | WO2015138438A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170035955A1 (en) * | 2015-03-27 | 2017-02-09 | Eliaz Therapeutics, Inc. | Apheresis based treatment for kidney disease |
| BR112018067693A2 (pt) * | 2016-03-04 | 2019-01-08 | Galectin Sciences Llc | compostos de selenogalactosídeo para a prevenção e tratamento de doenças associadas com galectina e usos dos mesmos |
| WO2017184851A1 (en) * | 2016-04-20 | 2017-10-26 | La Jolla Pharmaceutical Company | Compositions and methods for treating cancer |
| WO2018209255A1 (en) | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| US20200223921A1 (en) * | 2017-07-25 | 2020-07-16 | Immutics, Inc. | Treating cancer by blocking the interaction of tim-3 and its ligand |
| EP3466975A1 (en) * | 2017-10-05 | 2019-04-10 | Laboratoire Français du Fractionnement et des Biotechnologies | A specific binding molecule directed against galectin-3 protein |
| CN109498671A (zh) * | 2018-12-27 | 2019-03-22 | 浙江大学 | 一种防治糖尿病肾病的天然产物组合物及应用 |
| CA3127113A1 (en) | 2019-01-30 | 2020-08-06 | Dongxu Sun | Anti-gal3 antibodies and uses thereof |
| US20230107479A1 (en) * | 2020-03-23 | 2023-04-06 | G3 Pharmaceuticals, Inc. | Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection |
| US20230190373A1 (en) * | 2020-04-29 | 2023-06-22 | The University Of North Carolina At Charlotte | Methods and systems for surfactant enhanced laser-induced vapor bubbles for use in laser lithotripsy |
| CN115212226A (zh) * | 2021-04-20 | 2022-10-21 | 涛护集团有限公司 | 果胶在制备用于改善/逆转因病毒或药物损伤引起的慢性肾脏病的保健品/药物中的应用 |
| US20220411514A1 (en) * | 2021-06-08 | 2022-12-29 | Truebinding, Inc. | Anti-gal3 antibodies and methods of use for insulin resistance |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000007624A2 (en) * | 1998-08-06 | 2000-02-17 | Teijin Limited | Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix |
| US6890906B2 (en) * | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
| EP1617849B1 (en) * | 2003-04-07 | 2008-06-18 | Prospect Therapeutics, Inc. | Composition and uses of galectin antagonists |
| CN102439021B (zh) * | 2009-04-28 | 2015-09-02 | 格莱克特生物技术公司 | 半乳凝素的新型半乳糖苷抑制剂 |
| CN102477103B (zh) * | 2010-11-22 | 2014-09-10 | 中国科学院上海药物研究所 | 桔梗多糖及其降解产物,制备方法和用途 |
| CN102277398B (zh) * | 2011-07-18 | 2013-10-16 | 新乡医学院 | 高生物利用度改性果胶制备工艺及抗肿瘤应用 |
| MX360979B (es) * | 2011-09-16 | 2018-11-22 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico. |
-
2015
- 2015-03-10 CN CN201580024422.5A patent/CN106714812A/zh active Pending
- 2015-03-10 TW TW104107658A patent/TW201618794A/zh unknown
- 2015-03-10 EP EP15760917.3A patent/EP3125908A4/en not_active Withdrawn
- 2015-03-10 CA CA2942320A patent/CA2942320A1/en not_active Abandoned
- 2015-03-10 AU AU2015229658A patent/AU2015229658A1/en not_active Abandoned
- 2015-03-10 US US15/125,051 patent/US20170014446A1/en not_active Abandoned
- 2015-03-10 KR KR1020167027989A patent/KR20160122855A/ko unknown
- 2015-03-10 JP JP2016556316A patent/JP2017512205A/ja active Pending
- 2015-03-10 AR ARP150100715A patent/AR099707A1/es unknown
- 2015-03-10 WO PCT/US2015/019691 patent/WO2015138438A1/en active Application Filing
-
2016
- 2016-09-08 IL IL247699A patent/IL247699A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015138438A1 (en) | 2015-09-17 |
| CN106714812A (zh) | 2017-05-24 |
| EP3125908A4 (en) | 2017-11-15 |
| CA2942320A1 (en) | 2015-09-17 |
| TW201618794A (zh) | 2016-06-01 |
| KR20160122855A (ko) | 2016-10-24 |
| JP2017512205A (ja) | 2017-05-18 |
| IL247699A0 (en) | 2016-11-30 |
| US20170014446A1 (en) | 2017-01-19 |
| EP3125908A1 (en) | 2017-02-08 |
| AU2015229658A1 (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099707A1 (es) | Composiciones y métodos para tratar trastornos renales | |
| MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| EA201790737A1 (ru) | Комбинированная терапия | |
| UY36307A (es) | Terapias combinadas para el tratamiento del cáncer | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| EA201791516A1 (ru) | Способы комбинированного лечения злокачественных опухолей | |
| CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
| BR112017018964A2 (pt) | uso de plinabulin e métodos para tratar tumor cerebral | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| CO2019000753A2 (es) | Métodos para tratar el cáncer de próstata | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) | |
| MX2019005779A (es) | Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina. | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| MX2017000306A (es) | Metodos para tratar hipotension. | |
| EA201790427A1 (ru) | Замещенные бициклические соединения | |
| MX2017007054A (es) | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. | |
| MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
| MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
| EA201692202A1 (ru) | Способы лечения сердечно-сосудистых заболеваний | |
| MX2017013281A (es) | Metodos para tratar transtornos del almacenamiento lisosomal. | |
| EA201690446A1 (ru) | Лечение множественной миеломы | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |